Table 1.

Patient and disease characteristics

Treated with abemaciclib (N = 132)
Age in years, median (range)58 (36–89)
≥65 years, n (%)42 (31.8)
ECOG PS, n (%)
 073 (55.3)
 159 (44.7)
Disease locations, n (%)
 Visceral119 (90.2)
 Liver93 (70.5)
 Lung31 (23.5)
 Bone82 (62.1)
 Bone only3 (2.3)
Number of metastatic sites, n (%)
 119 (14.4)
 246 (34.8)
 ≥367 (50.8)
Prior endocrine therapy for metastatic disease
Number of regimens
 148 (36.4)
 225 (18.9)
 324 (18.2)
 ≥ 418 (13.6)
 Fulvestrant67 (50.8)
Prior chemotherapy for metastatic disease
Number of regimens
 167 (50.8)
 264 (48.5)
 31 (0.8)a
 Taxanesb91 (68.9)
 Capecitabine73 (55.3)
Other therapies for metastatic disease
 Everolimus37 (28.0)
 Investigational drug16 (12.1)
  • aPatient first received capecitabine and then received docetaxel; the patient had a break from docetaxel treatment and then restarted docetaxel without progression in between. The treatment with docetaxel was reported by the site as 2 regimens.

  • bThe remainder (31.1%) received prior taxane in the adjuvant setting.